共 85 条
Expert Opinion on Managing Chronic HCV in Patients with Non-Hodgkin Lymphoma and other Extrahepatic Malignancies
被引:8
作者:
Ferri, Clodoveo
[1
]
Feld, Jordan J.
[2
]
Bondin, Mark
[3
]
Cacoub, Patrice
[4
,5
,6
,7
,8
]
机构:
[1] Univ Modena & Reggio Emilia, Modena, Italy
[2] Univ Toronto, Toronto Gen Hosp, Toronto Ctr Liver Dis, Toronto, ON, Canada
[3] AbbVie Inc, Chicago, IL USA
[4] Sorbonne Univ, UPMC Univ Paris 06, UMR 7211, Paris, France
[5] Sorbonne Univ, Inflammat Immunopathol Biotherapy Dept DHU i2B, UPMC Univ Paris 06, Paris, France
[6] INSERM, UMR S 959, F-75013 Paris, France
[7] CNRS, FRE3632, F-75005 Paris, France
[8] Grp Hosp Pitie Salpetriere, AP HP, Dept Internal Med & Clin Immunol, F-75013 Paris, France
来源:
关键词:
HEPATITIS-C-VIRUS;
MARGINAL ZONE LYMPHOMA;
B-CELL LYMPHOMAS;
ANTIVIRAL THERAPY;
HEPATOCELLULAR-CARCINOMA;
THYROID-CANCER;
LICHEN-PLANUS;
INFECTION;
RISK;
MANIFESTATIONS;
D O I:
10.3851/IMP3250
中图分类号:
R51 [传染病];
学科分类号:
100401 ;
摘要:
HCV is a carcinogen that is well established as a major risk factor for hepatocellular carcinoma. Evidence that HCV plays a role in the development of extrahepatic malignancies is less robust; however, epidemiological studies have consistently demonstrated an association between HCV infection and B-cell non-Hodgkin lymphoma (NHL). The strongest evidence for a link between HCV and tumouri-genesis is the clear association between viral eradication, as indicated by achievement of sustained virological response, and remission of B-cell NHL. All-oral direct-acting antiviral-based therapies are effective in patients with HCV-associated NHL and well tolerated. For this reason, it is important that clinicians assess HCV-infected patients for HCV-associated extrahepatic malignancies so patients can receive timely diagnosis and treatment.
引用
收藏
页码:23 / 33
页数:11
相关论文